Healio Gastroenterology Current Issue
The following articles appeared in the print edition of Healio Gastroenterology.
Table of Contents
- No patient left behind: MASLD rebranding provides ‘affirmative diagnosis’ without stigma Kate Burba
-
- Nomenclature change brings new opportunities for research, drug development Stephen A. Harrison, MD, FAASLD
- Direct-acting antiviral use remains low, despite improved survival in HCV-related HCC Monica Stonehill
- FDA approves Pfizer’s Velsipity as ‘oral, once-daily pill’ for ulcerative colitis
- Gut microbiome associated with precancerous lesions, future onset of colorectal cancer Monica Stonehill
- Individuals with low birthweight 4 times more likely to develop NAFLD later in life Kate Burba
- ‘It is very clear’: Blocking TL1A an important factor in treatment of ulcerative colitis Kate Burba
- MASH now top indication for liver transplantation in those with hepatocellular carcinoma Monica Stonehill
- Olympus issues class I recall for insufflation unit after '10 serious injuries, one death'
-
- Patients with IBD at increased risk for respiratory syncytial virus infection Kate Burba
- Q&A: Providers must listen, recognize GI ‘alarm signals’ in pediatric patients Kate Burba; Dedrick Moulton, MD
- Sensitivity of next-generation Cologuard in precancer detection ‘numerically exceeded’ FIT Kate Burba
- Serum testing may simplify diagnostic criteria, avoid biopsy in suspected celiac disease Kate Burba
- Shift from NAFLD to MASLD does not necessarily require change in management Katrina Altersitz
- Replacing meat with plant, dairy protein curbs ammonia generation in cirrhosis Robert Stott
- Treatment for alcohol use disorder linked to lower odds for mortality in patients with ALD Kate Burba
- VIDEO: Risankizumab a ‘great option for patients,’ induces clinical remission in UC Edward V. Loftus Jr., MD; Kate Burba
-
- VIDEO: TERN-501 ‘could be a best-in-class molecule’ alone, as combination therapy for MASH Kate Burba; Erin Quirk, MD
- VIVID-1 trial: More than half of mirikizumab users achieve clinical remission in Crohn’s
- Voquezna back on track with FDA approval for erosive esophagitis, heartburn relief